Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | MC4R | P32245 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24023435 | 0.88 | ALDH1A1 (0.62) | SIGMAR1KDM4EALDH1A1POLBCYP2A13 | |
| SCHEMBL18396749 | 0.88 | SIGMAR1 (0.65) | SIGMAR1KDM4EALDH1A1POLBMC4R | |
| SCHEMBL2075836 | 0.88 | SIGMAR1 (0.59) | SIGMAR1KDM4EALDH1A1POLBMEN1 | |
| SCHEMBL1041303 | 0.84 | SIGMAR1 (1.00) | SIGMAR1POLBKMT2AMC4RDRD4 | |
| SCHEMBL242970 | 0.84 | SIGMAR1 (1.00) | SIGMAR1POLBKMT2AMC4RDRD4 | |
| SCHEMBL1415730 | 0.84 | SIGMAR1 (1.00) | SIGMAR1POLBKMT2AMC4RDRD4 | |
| SCHEMBL8188324 | 0.84 | SIGMAR1 (1.00) | SIGMAR1POLBKMT2AMC4RDRD4 | |
| SCHEMBL2489199 | 0.84 | SIGMAR1 (1.00) | SIGMAR1POLBKMT2AMC4RDRD4 | |
| SCHEMBL576868 | 0.84 | SIGMAR1 (1.00) | SIGMAR1POLBKMT2AMC4RDRD4 | |
| SCHEMBL27790866 | 0.82 | DRD2 (0.59) | SIGMAR1KDM4EALDH1A1POLBDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113087684-B | Application of bis (triphenylphosphine) carbonyl ruthenium dichloride monohydrate | 浙江工业大学 | 2022-06-21 | — | — | CN | claimed |
| CN-113087684-A | Application of bis (triphenylphosphine) carbonyl ruthenium dichloride monohydrate | 浙江工业大学 | 2021-07-09 | — | — | CN | claimed |
| EP-2336315-B1 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION AS (DK) | 2017-07-19 | — | — | EP | claimed |
| CN-103910658-B | A kind of sulfide oxidation becomes the method for sulfone | 宁夏大学 | 2016-08-17 | — | — | CN | claimed |
| CN-103910658-A | Method of oxidizing thioether to sulfone | UNIV NINGXIA | 2014-07-09 | — | — | CN | claimed |
| WO-2013117771-A2 | COSMETIC TREATMENT METHOD, AND COMPOSITION COMPRISING A GLYOXYLIC ACID DERIVATIVE | L'OREAL (FR) | 2013-08-15 | — | — | WO | claimed |
| EP-2336315-A2 | Enzymatic encoding methods for efficient synthesis of large libraries | Nuevolution A/S (DK) | 2011-06-22 | — | — | EP | claimed |
| US-4016263-A | BACTERICIDES | BOEHRINGER INGELHEIM GMBH (DT) | 1977-04-05 | — | — | US | claimed |
| WO-2025028365-A1 | PHOTOCHROMIC COMPOUND, PHENOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASS | 株式会社トクヤマ | 2025-02-06 | — | — | WO | disclosed |
| WO-2024204554-A1 | SPIROCYCLIC MORPHINAN DERIVATIVE | 日本ケミファ株式会社 | 2024-10-03 | — | — | WO | disclosed |
| US-11702652-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2023-07-18 | — | — | US | disclosed |
| US-20230087342-A1 | AZEPANE DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-03-23 | — | — | US | disclosed |
| EP-4116303-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | Loxo Oncology, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-0054748-B1 | PROCESS FOR THE PREPARATION OF AQUEOUS SOLUTIONS OF CATIONIC ORGANOSILICIUM COMPOUNDS | Degussa Aktiengesellschaft (DE) | 1984-09-26 | — | — | EP | disclosed |
| US-4390712-A | Aqueous solution of cationic organosilicon compounds and process for the production of the solutions | DEGUSSA AG (DE) | 1983-06-28 | — | — | US | disclosed |
| EP-0054748-A2 | Process for the preparation of aqueous solutions of cationic organosilicium compounds | Degussa Aktiengesellschaft (DE) | 1982-06-30 | — | — | EP | disclosed |
| US-4332937-A | DYES FOR POLYACRYLONITRILE | CIBA-GEIGY CORPORATION (US) | 1982-06-01 | — | — | US | disclosed |
| US-4016263-A | BACTERICIDES | BOEHRINGER INGELHEIM GMBH (DT) | 1977-04-05 | — | — | US | disclosed |
| US-4016263-A | BACTERICIDES | BOEHRINGER INGELHEIM GMBH (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230087342-A1 | AZEPANE DERIVATIVE | ADCY10, AZI2, PRMT1 | SIGMAR1 186/4885KDM4E 1089/4885ALDH1A1 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.